Annovis Bio Inc (ANVS) Stock Price, Quote & News

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 875 3192

Website: www.annovisbio.com

Address:

101 Lindenwood Drive, Suite 225, Malvern, United States

junkjar291 Sep. 17 at 4:18 AM

$ANVS This turd is going down since sept2 with high volume, shorts are relentless and institute might be getting out since market cap is below $50M

0 · Reply

junkjar291 Sep. 17 at 4:12 AM

$ANVS Wow! This mfrs has no bottom. Maria needs to go, she may be great lab PI but she is terrible to run any company, not sure what she was thinking during last webinar, she said she is "little chicken" when it comes to start marketing effort after 6month readout, she wasn't confident. At this rate this will be in gutter before Oct raise. How is she going to raise any money even for 6month readout? She has a dream of raising money at $0.35 with truck load of warrants.

0 · Reply

donemedirty Sep. 17 at 12:53 AM

$ANVS vote no and sell the company

0 · Reply

kgw567 Sep. 16 at 10:13 PM

$ANVS They just had a vote for company officers, if you weren't satisfied, you should have voted. I voted through Schwab my broker. You should have been paing attention. The core group ain't going anywhere, they are voted in.

0 · Reply

LongOrShortToMakeMoney Sep. 16 at 8:19 PM

$ANVS oh La la

0 · Reply

Ronin2060 Sep. 16 at 7:34 PM

$ANVS i voted against . We must protect our shares and not accept dilution

3 · Reply

nhyujm6 Sep. 16 at 6:43 PM

$ANVS The asymmetry here is now crazy. I have a large position, but we need to do something about Maria's complete ineptitude from a basic corporate governance and stakeholder communication perspective. My proposal is that we draft a simple paragraph calling for a new CEO, for her to step aside to COO, list everyone's name and the number of shares each name represents, and then send it to the Board. I'm happy to organize this. Like this post if you are willing to participate.

2 · Reply

Dopamineaddict Sep. 16 at 4:55 PM

$ANVS Why 100% p-tau217+ enrichment in the Ph3 trial is a statistical game changer: In an unselected AD population, placebo controls drop only ~1.0–1.5 pts on ADCS-iADL over 6 months. When the control group barely moves, noise dominates & proving treatment separation is brutal. p-tau217+ enrichment fixes the placebo curve: • Unselected Placebo: ~1.0 - 1.5 pt drop • p-tau217+ Placebo: ~1.8 - 2.5 pt drop That steeper drop eliminates statistical noise and creates a much wider separation window for Buntanetap to hit p < 0.05 on function. Ph2 3-month data already showed early functional improvement signals in p-tau217+ patients. While 12 weeks was too short for stat sig on ADCS-iADL, extending the timeframe to 6 months against a rapidly declining enriched placebo arm gives Buntanetap the exact setup it needs to widen the delta and score a dual hit on cognition & function. I am not an expert. I am a low IQ Individual. Do your own research!

1 · Reply

SevenPhigs27 Sep. 16 at 4:02 PM

$ANVS Took a starter GLTA

0 · Reply

ILikeDaStocks Sep. 16 at 3:45 PM

$ANVS @ReturnOfEsquire My pick has always been ANVS, not AVXL, not SAVA. I thought the other two might be somewhat effective (slightly), but that didn't happen. IMO, ANVS is so cheap because of the failure of other companies in the space and the belief that ALL will follow the same path...which is correct...until it isn't!! My bet remains - buntanetap and ANVS! IF correct, the gains for investors and patients/families in need are not easily calculated! 👍

0 · Reply

Annovis Bio Proxy statement: Proxy filing

Sep 2, 2026, 4:00 PM EDT - 14 days ago

Annovis Bio Transcript: Investor update

2026-08-27T23:00:11.000Z - 20 days ago

Annovis Bio price target lowered to $7 from $8 at Roth Capital

Aug 25, 2026, 8:00 AM EDT - 22 days ago

Annovis to Host Corporate Update Webinar on September 2, 2026

Aug 25, 2026, 8:00 AM EDT - 22 days ago

Annovis Bio Proxy statement: Proxy filing

Aug 14, 2026, 8:00 AM EDT - 4 weeks ago

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Aug 14, 2026, 7:00 AM EDT - 4 weeks ago

Annovis Bio Earnings release: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 4 weeks ago

Annovis Bio Quarterly report: Q2 2026

Aug 3, 2026, 9:00 AM EDT - 6 weeks ago

Annovis Bio Slides: Investor presentation

2026-07-07T20:16:13.000Z - 2 months ago

Annovis Bio initiated with a Buy at Roth Capital

2026-07-07T11:20:30.000Z - 2 months ago

Annovis Bio announces full enrollment for buntanetap trial

Jul 7, 2026, 7:00 AM EDT - 2 months ago

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease

2026-07-01T12:05:20.000Z - 2 months ago

Annovis Bio promotes Cheng Fang to chief scientific officer

Jul 1, 2026, 8:00 AM EDT - 2 months ago

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

2026-05-26T15:07:38.000Z - 3 months ago

Annovis Bio regains NYSE listing compliance

May 26, 2026, 8:00 AM EDT - 3 months ago

Annovis Bio Regains NYSE Listing Compliance

2026-05-20T12:20:11.000Z - 3 months ago

Annovis Bio 7.9M share Spot Secondary priced at $1.90

May 20, 2026, 8:00 AM EDT - 3 months ago

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

2026-05-19T20:12:17.000Z - 4 months ago

Annovis Bio announces common stock and warrants offering, no amount given

May 19, 2026, 4:06 PM EDT - 4 months ago

Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

May 15, 2026, 7:30 AM EDT - 4 months ago

Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

May 15, 2026, 7:00 AM EDT - 4 months ago

Annovis Bio Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 4 months ago

Annovis Bio Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 4 months ago

Annovis Bio Slides: Corporate presentation

May 7, 2026, 7:30 AM EDT - 4 months ago

Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Annovis Bio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Annovis Bio Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Apr 10, 2026, 8:30 AM EDT - 5 months ago

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Apr 9, 2026, 8:30 AM EDT - 5 months ago

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

Apr 8, 2026, 7:00 AM EDT - 5 months ago

Annovis Bio Slides: Corporate presentation

2026-04-02T11:54:03.000Z - 5 months ago

Annovis Bio secures U.S. patent for buntanetap

Apr 2, 2026, 7:30 AM EDT - 5 months ago

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Annovis Publishes Historical Review of Buntanetap in The Scientist

Mar 24, 2026, 7:00 AM EDT - 5 months ago

Annovis Bio Slides: Corporate presentation

2026-03-19T11:56:46.000Z - 6 months ago

Annovis Bio enters partnership with NeuroRPM

Mar 19, 2026, 7:30 AM EDT - 6 months ago

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

Mar 19, 2026, 7:30 AM EDT - 6 months ago

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

2026-03-16T11:41:50.000Z - 6 months ago

Annovis Bio sees cash runway to 3Q26

2026-03-16T11:35:20.000Z - 6 months ago

Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year

Mar 16, 2026, 7:30 AM EDT - 6 months ago

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Mar 16, 2026, 7:00 AM EDT - 6 months ago

Annovis Bio Earnings release: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 6 months ago

Annovis Bio Annual report: Q4 2025

Mar 3, 2026, 8:00 AM EST - 6 months ago

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

2026-02-12T13:21:18.000Z - 7 months ago

Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap

Feb 12, 2026, 8:00 AM EST - 7 months ago

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease

2025-12-18T21:40:13.000Z - 9 months ago

Annovis Bio reports open-label extension study for Parkinson’s disease patients

Dec 18, 2025, 4:35 PM EST - 9 months ago

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Dec 16, 2025, 8:00 AM EST - 9 months ago

Annovis to Host Corporate Update Webinar on January 28, 2026

Dec 3, 2025, 8:00 AM EST - 9 months ago

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Nov 24, 2025, 8:00 AM EST - 9 months ago

Annovis Announces Two Presentations at the CTAD 2025 Conference

2025-11-18T14:39:45.000Z - 10 months ago

Annovis announces FDA meeting to discuss PDD program

Nov 18, 2025, 8:00 AM EST - 10 months ago

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

2025-11-17T13:10:41.000Z - 10 months ago

Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s

Nov 17, 2025, 8:00 AM EST - 10 months ago

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

2025-11-12T13:11:18.000Z - 10 months ago

Annovis Bio reports Q3 EPS (37c) vs. (97c) last year

2025-11-12T13:10:52.000Z - 10 months ago

Annovis Bio sees cash runway to 3Q26

Nov 12, 2025, 8:00 AM EST - 10 months ago

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:00 AM EST - 10 months ago

Annovis Bio Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Annovis Bio Quarterly report: Q3 2025

2025-11-06T13:32:03.000Z - 10 months ago

Annovis Bio says all 84 sites fully activated for Phase 3 study in early AD

Nov 6, 2025, 8:00 AM EST - 10 months ago

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

2025-10-27T12:05:25.000Z - 10 months ago

Annovis Bio prices 1.67M shares at $2.05 in registered direct offering

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Oct 15, 2025, 5:15 PM EDT - 11 months ago

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

Oct 10, 2025, 8:31 AM EDT - 11 months ago

Annovis Announces $6 Million Registered Direct Offering of Common Stock

Oct 9, 2025, 7:30 AM EDT - 11 months ago

Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

Sep 25, 2025, 7:30 AM EDT - 11 months ago

Annovis Appoints Mark Guerin as Chief Financial Officer

Sep 16, 2025, 7:30 AM EDT - 1 year ago

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Sep 10, 2025, 12:00 PM EDT - 1 year ago

Annovis Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:05 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Quarterly report: Q2 2025

Aug 12, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Jun 24, 2025, 4:30 PM EDT - 1 year ago

Annovis Bio Transcript: Status Update

Jun 19, 2025, 6:30 AM EDT - 1 year ago

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Annovis to Host Webinar and Live Q&A on June 24, 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

May 13, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q1 2025

May 13, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Quarterly report: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Mar 21, 2025, 5:05 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 21, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Annual report: Q4 2024

Mar 21, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Feb 19, 2025, 8:30 AM EST - 1 year ago

Annovis to Host Patients' Live Forum on February 27, 2025

Feb 7, 2025, 8:00 AM EST - 1 year ago

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Feb 4, 2025, 4:31 PM EST - 1 year ago

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Feb 3, 2025, 6:22 AM EST - 1 year ago

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

junkjar291 Sep. 17 at 4:18 AM

$ANVS This turd is going down since sept2 with high volume, shorts are relentless and institute might be getting out since market cap is below $50M

0 · Reply

junkjar291 Sep. 17 at 4:12 AM

0 · Reply

donemedirty Sep. 17 at 12:53 AM

$ANVS vote no and sell the company

0 · Reply

kgw567 Sep. 16 at 10:13 PM

0 · Reply

LongOrShortToMakeMoney Sep. 16 at 8:19 PM

$ANVS oh La la

0 · Reply

Ronin2060 Sep. 16 at 7:34 PM

$ANVS i voted against . We must protect our shares and not accept dilution

3 · Reply

nhyujm6 Sep. 16 at 6:43 PM

2 · Reply

Dopamineaddict Sep. 16 at 4:55 PM

1 · Reply

SevenPhigs27 Sep. 16 at 4:02 PM

$ANVS Took a starter GLTA

0 · Reply

ILikeDaStocks Sep. 16 at 3:45 PM

0 · Reply

NolAsrtormZ Sep. 16 at 3:31 PM

$ANVS Why this flops around like a fish Took small position in $SXTP 2.6 million share float

0 · Reply

ReturnOfEsquire Sep. 16 at 2:41 PM

$ANVS I remember the days when we would hotly debate with SAVA and AVXL shareholders which company would become a 100B company. What a bunch of fools we all were.

2 · Reply

ScottHopko Sep. 16 at 1:48 PM

$ANVS Oversold, adding here.

1 · Reply

Dopamineaddict Sep. 16 at 2:05 AM

$ANVS The shorts here are relentlessly at work inciting panic. The upside on this bet remains unmatched and well worth the risk. March will be intense.

1 · Reply

noviceEve Sep. 16 at 12:52 AM

$ANVS Maria after she gets the nasdaq delisting notice.

2 · Reply

ReturnOfEsquire Sep. 15 at 7:20 PM

$ANVS WOW...haven’t been following. Just an organic decline? Sorry, guys, except @philtheclown

1 · Reply

Dopamineaddict Sep. 15 at 4:19 PM

$ANVS My FOMO nightmare: Maria has been pumping the ATM, and combined with preferred shares, she has collected $8 million. She then raises the remaining 7 million mostly through insider buying and announces it with some OLE data. Consequently, I miss these bargain prices.

1 · Reply

Dopamineaddict Sep. 15 at 3:48 PM

$ANVS Michael Hoffman is sick of being a millionaire. He needs to be a billionaire, and he knows purchasing more Annovis shares is the way to it.

0 · Reply

Dopamineaddict Sep. 15 at 1:48 PM

$ANVS Something like this might help:

2 · Reply

Alex1710 Sep. 15 at 12:52 AM

$ANVS $0,85 - $0,95 cents this week. At first a r/s then a financing before year end. A $48,5 MC is a joke , just like a start up biotech in preclinical studies. Even some start up biotech on the Canadian micro cap exchange worth more than that. A real piece of shit.

2 · Reply

joshszary Sep. 14 at 11:59 PM

$ANVS averaged down, sitting on a cost basis of $1.50

2 · Reply

ILikeDaStocks Sep. 14 at 9:05 PM

$ANVS Anyone worrying about a reverse split because ANVS is trading in the low $1 range is way premature. A company receives a delinquency notice after its stock has an average closing price below $1.00 for 30 consecutive trading days, and ANVS has yet to close below $1 for one day. Then the NYSE gives the company at least six months (likely longer) to regain compliance. And we all know ANVS has a MAJOR readout coming 6-months from this week. Now that's worth worrying about!! 😧

0 · Reply

Market Cap	47.80M
Revenue (ttm)	0.00
Net Income (ttm)	-28.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,432,800
Avg Vol	915,342
Day's Range	N/A - N/A
Shares Out	42.68M
Stochastic %K	0%
Beta	1.24
Analysts	Strong Sell
Price Target	$10.50